| Date Filed | Type | Description |
| 09/29/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/23/2023 |
4
| Marks Jason M. (Director) has filed a Form 4 on BiomX Inc.|
Txns:
| Granted 41,000 options to buy
@ $0.363, valued at
$14.9k
|
|
| 08/23/2023 |
4
| Dambach Michael E. (Director) has filed a Form 4 on BiomX Inc.|
Txns:
| Granted 41,000 options to buy
@ $0.363, valued at
$14.9k
|
|
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/12/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/08/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/24/2023 |
4
| Oron Assaf (Chief Business Officer) has filed a Form 4 on BiomX Inc.|
Txns:
| Bought 3,192 shares
@ $0.2731, valued at
$871.7 |
|
| 05/19/2023 |
3
| Marks Jason M. (Director) has filed a Form 3 on BiomX Inc. |
| 05/19/2023 |
3
| Dambach Michael E. (Director) has filed a Form 3 on BiomX Inc. |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
SC 13D/A
| OrbiMed Israel BioFund GP Limited Partnership reports a 9.9% stake in BiomX Inc. |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
4
| OrbiMed Israel BioFund GP Limited Partnership (10% Owner) has filed a Form 4 on BiomX Inc.|
Txns:
| Bought 348,000 shares
@ $0.245, valued at
$85.3k
Bought 1,789,959 warrants
@ $0.244, valued at
$436.7k
|
|
| 03/17/2023 |
SC 13D/A
| OrbiMed Israel BioFund GP Limited Partnership reports a 10.5% stake in BiomX Inc. |
| 03/09/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/08/2023 |
SC 13G
| Cystic Fibrosis Foundation reports a 8.1% stake in BiomX Inc. |
| 02/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ... |
| 02/14/2023 |
SC 13G/A
| MMCAP International Inc. SPC reports a 7.1% stake in BiomX Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/26/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|